 Aclaris Therapeutics NASDAQ:ACRS was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists ... 